Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 10/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31109299 | 0.96 | F10 (0.41) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL31109317 | 0.95 | F10 (0.42) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL29113404 | 0.92 | F10 (0.43) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL31109312 | 0.92 | F10 (0.43) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL29113444 | 0.92 | TACR1 (0.39) | F10F2MEN1KMT2A | |
| SCHEMBL31109220 | 0.91 | F2 (0.43) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL13143762 | 0.89 | F10 (0.44) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL22837948 | 0.89 | F10 (0.44) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL13120953 | 0.89 | F10 (0.44) | F10ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL29113408 | 0.89 | ALDH1A1 (0.45) | F10ALDH1A1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615515-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | ITGA4, ITGB3, ITGB5 | F10 639/4885ALDH1A1 232/4885LMNA 2963/4885 |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB4 | F10 825/4885ALDH1A1 141/4885LMNA 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.